Art

J-GLOBAL ID：202002268506253110   Reference number：20A0872042

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis

骨髄線維症患者における肺高血圧症と心機能に対するJanusキナーゼ1/2阻害剤ルキソリチニブの長期効果

Author (11)： Miyawaki Hiroshi (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Kioka Hidetaka (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Sato Kazuaki (Department of Pathology, Osaka University Graduate School of Medicine, Japan) ,  Kurashige Masako (Department of Pathology, Osaka University Graduate School of Medicine, Japan) ,  Ozawa Takayuki (Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan) ,  Shibayama Hirohiko (Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan) ,  Hikoso Shungo (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Morii Eiichi (Department of Pathology, Osaka University Graduate School of Medicine, Japan) ,  Yamauchi-Takihara Keiko (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Yamauchi-Takihara Keiko (Health Care Center, Osaka University, Japan) ,  Sakata Yasushi (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 59  Issue： 2  Page： 229-233(J-STAGE)  Publication year： 2020 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： JAK/STAT ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0872042&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (5)： onco-cardiology ,  pulmonary hypertension ,  tyrosine kinase inhibitor ,  cardiotoxicity ,  myelofibrosis

JST classification (2)： Drug therapy(=pharmacotherapy)for hematologic diseases in general  (GK05020P) ,  Cardiovascular system diseases  (GJ03000C)

Substance index (1)： Ruxolitinib

Reference (15)：

• 1. Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol 91: 50-58, 2016.
• 2. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91: 1262-1271, 2016.
• 3. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.
• 4. Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia 28: 1486-1493, 2014.
• 5. Yamauchi-Takihara K, Kishimoto T. A novel role for STAT3 in cardiac remodeling. Trends Cardiovasc Med 10: 298-303, 2000.

Terms in the title (8)： 骨髄線維症 ,  患者 ,  肺高血圧症 ,  心機能 ,  Janusキナーゼ1 ,  阻害剤 ,  ルキソリチニブ ,  長期効果